Sharon Schulzki: New COO of CARLSMED

Sharon Schulzki, who led the exit of Tissue Regeneration Systems (TRS) to J&J DePuy Synthes and the licensing of TRS’s proprietary mineral coating technology to Medtronic Spine, is the new chief operating officer of CARLSMED, Inc.

According to the company, Schulzki has “deep experience building venture backed MedTech startups and has excelled in prior executive leadership roles with market leaders Stryker and Johnson & Johnson’s DePuy Synthes.”

“We’ve made tremendous progress during the last year, and today I’m pleased to announce that Sharon has joined the team as COO,” said Mike Cordonnier, company CEO and co-founder. “Sharon’s track record of building value through execution of Evidence Development Plans and key surgeon engagement will ensure that CARLSMED’s platform achieves the mission of making personalized medical devices the preferred treatment option.”

Schulzki told OTW, “My first step in this new role is to collaborate with the world’s leading spine surgeons to deliver CARLSMED’s transformative solution to complex spine surgery. After previewing the power of this platform, these surgeons are genuinely excited about finally being able to achieve a personalized surgical plan in the operating room with truly personalized interbody devices.”

“Even though new technologies are constantly being introduced into the spine market, this is a critical element that’s been completely missing. I really enjoy watching their reactions when they see what CARLSMED can deliver.”